Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem vs Cefotaxime in Spontaneous Bacterial Peritonitis
NCT05427747Phase 4
Key facts
- Status
- Unknown
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Sponsor
- Assiut University
- Modality
- Small Molecules
- Drugs
- meropenem
- Conditions
- spontaneous bacterial peritonitis (SBP)
01
Overview
Phase 4, randomised trial of meropenem in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Assiut University. Primary endpoint: Response to treatment within 5 days. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Cefotaxime Arm
Standard of care antibiotic treatment
Meropenem Arm
Experimental antibiotic treatment
03
Who it enrols
Adults (18-80) with liver cirrhosis and ascites (PMN > 250/mm3), excluding those with recent abdominal surgery, secondary/tuberculous peritonitis, malignancy, or AIDS.
04
Endpoints
Primary
Response to treatment within 5 days
Beyond the preview
Go deeper on NCT05427747.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427747.